‍

Developed by a consortium of 24 partners and funded by the Innovative Health Initiative (IHI), an EU public-private partnership funding health research and innovation, the Real-World Implementation, Deployment, and Validation of Early Detection Tools and Lifestyle Enhancement (AD-RIDDLE) project will offer healthcare providers a toolbox platform of validated resources and tailored interventions to help detect, diagnose, prevent, and treat Alzheimer’sdisease.

The AD-RIDDLE programme will offer healthcare professionals a suite of validated solutions for timely detection and diagnosis of Alzheimer’s disease and dementias, to match individuals with the right interventions at the right time, enabling people to better understand what they can do to reduce risk and prevent cognitive decline.

Alzheimer’s disease represents a major public health challenge. In Europe alone, around 7million people are living with Alzheimer’s disease, a figure that is expected to double by 2050. There is a pressing need for effective preventive, diagnostic and therapeutic solutions, implemented at scale, and for increased engagement of individuals and caregivers with disease prevention, management and care. The advent of disease modifying therapies will lead to more people seeking diagnosis and treatment. While this initially represents an increasing cost to health systems and society at large, it also presents enormous potential for prevention, opportunities for more timely diagnosis and personalised treatment options, and overall health-economic benefits in the long term.
‍

“AD-RIDDLE represents the latest chapter in our long series of projects centred on the fight against Alzheimer’s and neurodegenerative disorders – a trajectory that comprises flagship research projects such as EPAD, AMYPAD, ROADMAP, NEURONET and the recently started PROMINENT. Bringing reliable Alzheimer’s biomarkers into standard clinical practice is expected to have a decissive impact on the prevention, early diagnosis and treatment of such a devastating disease. We will do our very best to help an outstanding research team to achieve these groundbreaking goals over the next few years.”  - Carlos Díaz (CEO - SYNAPSE)

AD-RIDDLE aims to unlock efficiencies for AD diagnosis and treatment, removing barriers to entry that traditionally slow down patient access to healthcare providers and precision medicine. The project will create a modular toolbox platform designed to provide support at all stages of the clinical pathway, including:
‍

• A digital community engagement portal, including self-guided assessment tools for older adults, pathways for timely referral to healthcare providers, and resources that are tailored and actionable.
  ‍
• An array of screening tools for increased accuracy in risk detection and early diagnosis, including digital cognitive assessments and blood-based biomarkers.
  ‍
• A decision support toolkit for healthcare providers, powered by validated algorithms for differential diagnoses, prevention, and care.
  ‍
• Personalised patient therapies which can be physician-supported or self-guided, including lifestyle interventions and pharmacological treatments, matching patients to the right interventions at the right time.

‍

More information:

Press release